Skip to main content
Clinical Trials/NCT05697315
NCT05697315
Completed
Not Applicable

The Effect of Erector Spinae Block for Postoperative Pain Management Cesarean Delivery Patients

Kahramanmaras Sutcu Imam University1 site in 1 country56 target enrollmentDecember 1, 2021

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pain
Sponsor
Kahramanmaras Sutcu Imam University
Enrollment
56
Locations
1
Primary Endpoint
24-hour opioid consumption
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Erector spinae plane (ESP) block is an interfacial plane block with visceral and somatic analgesic activity at paraspinal muscles. This study aims to examine the postoperative analgesic efficacy of ESP block after cesarean section (CS) with Pfannenstiel incision under spinal anesthesia.

Detailed Description

The study included 54 patients with mild systemic disease (ASA II patients) who would undergo elective CS under spinal anesthesia. They were randomly divided into an ESP block group (Group E) and a control group (Group C). After the surgery, Group E patients underwent ultrasound-guided bilateral ESP block with 20 ml of 0.25% bupivacaine at the lateral decubitus position, while Group C received no intervention. Patients in both groups received parenteral patient-controlled analgesia. The patients' post-operative 24-hour opioid consumption, regular Visual Analogue Scale (VAS) measurements, and need for rescue analgesics were evaluated. Statistical analysis was performed using SPSS 21 program. Demographic and other data were assessed using independent samples t-test, Mann-Whitney U test, and Chi-square analysis.

Registry
clinicaltrials.gov
Start Date
December 1, 2021
End Date
April 1, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Female

Investigators

Sponsor
Kahramanmaras Sutcu Imam University
Responsible Party
Principal Investigator
Principal Investigator

Gökçe Gişi

Assistant Professor

Kahramanmaras Sutcu Imam University

Eligibility Criteria

Inclusion Criteria

  • ASA II patients
  • 18-45 years who underwent CS with Pfannenstiel incision under spinal anesthesia
  • agreed to participate in the study

Exclusion Criteria

  • Patients with infection at the injection site
  • Coagulopathy Allergy to amide-type local anesthetics
  • History of peripheral neuropathy
  • Hepatic and/or renal failure
  • Refusing the procedure
  • patients with heart disease

Outcomes

Primary Outcomes

24-hour opioid consumption

Time Frame: up to 24 hour

The amount of tramadol consumed in milligrams in the first 24 hours was determined with a patient-controlled analgesia pump.

Secondary Outcomes

  • Visual Analog Scale (Vas)(0, 30 minutes, 1 hour, 2 hours, 6 hours, 12 hours, 24 hours)

Study Sites (1)

Loading locations...

Similar Trials